Skip to main content
SpringerLink
Log in

The Tysabri [natalizumab] product information should be updated to warn doctors and patients that liver injury may occur

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMEA.EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed. Media Release: 20 Mar 2008. Available from: URL: http://www.emea.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The Tysabri [natalizumab] product information should be updated to warn doctors and patients that liver injury may occur. React. Wkly. 1196, 4 (2008). https://doi.org/10.2165/00128415-200811960-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811960-00010

Keywords

Search

Navigation